-
World Cup: Eight teams remain in the hunt for glory
-
Former Real Madrid coach Arbeloa named Fulham manager
-
'A nice surprise': Marathon man Djokovic revels in Wimbledon epic
-
Messi inspires Argentina great escape over Egypt, Swiss advance
-
Switzerland beat Colombia on penalties to reach World Cup quarter-finals
-
US strikes Iran after Hormuz attacks, Tehran threatens response
-
Djokovic survives Wimbledon's longest quarter-final to book Sinner blockbuster
-
Djokovic wins five-hour epic to earn Sinner showdown at Wimbledon
-
'Flunked': US soccer seeks answers as World Cup dream shattered
-
US strikes Iran after Hormuz tanker attacks: military
-
Mbappe revels in captain's role for France at World Cup
-
Messi 'didn't want to go home' as Argentina comeback stuns Egypt
-
Iyer's India 'atrocious' in record 125-run T20 defeat by England
-
Netflix strikes deals in short-form video push
-
Rain hands West Indies series win over Sri Lanka
-
The height factor: how a small building survived Venezuela's quakes
-
World Cup exit puts another nail in America's summer of fun
-
Egypt 'cheated' in controversial World Cup exit to Messi's Argentina, says Hassan
-
US revokes Iran oil waiver after Hormuz tanker attacks
-
Global AI industry falls short on safety, think tank warns
-
England quicks star as India suffer record 125-run T20 defeat
-
'History made': Egyptian pride despite World Cup heartbreak
-
Cardinal tipped to be pope accused of molesting several women
-
How rescuers carried out 180-hour 'miracle' amid Venezuela's ruins
-
How rescuers carried out 180-hour 'miracle' amid Venzuela's ruins
-
Victorious Belgian footballers troll Trump with YMCA dance
-
I can still win another Grand Slam, says Osaka after Wimbledon exit
-
Scotland boss Townsend expects Russell will face Springboks
-
France's Le Pen says still running for president
-
Messi inspires Argentina great escape over Egypt
-
Argentina produce epic World Cup fightback to beat Egypt, reach quarters
-
Zverev, Cobolli targeting rematch at Wimbledon
-
Canada province preparing lawsuit against OpenAI over school shooting
-
Colombia president-elect accuses outgoing leader of 'coup' plotting
-
Lidl-Trek celebrate 'perfect' day at Tour de France
-
IOC eases restrictions on Russians before 2028 LA Games as anthem, flag ban remains
-
Cavs agree on Mitchell deal as LeBron watches: report
-
Muchova ends Osaka run to reach Wimbledon semis
-
Turkish delight: Trump revels in Erdogan's lavish welcome
-
Mexico probing if US violated sovereignty in 2024 drug lord capture
-
Nigeria's Dangote confirms Lamu, Kenya for east Africa mega-refinery
-
Zverev reaches first Wimbledon quarter-final
-
Study points to likely route for Hannibal's legendary Alpine crossing
-
Nordic joy as Traeen takes yellow, Pedersen wins Tour de France 4th stage
-
Australia's Mooney back at No 1 in batting rankings after World Cup heroics
-
Electric Our Lady land: guitar made from burned Notre Dame wood
-
Traeen takes yellow, Pedersen wins Tour de France 4th stage
-
Tanker attacks send oil higher, stocks hit by AI jitters
-
UK hard-right leader Farage resigns as MP to force snap vote in finances row
-
IOC shuffle 2030 Winter Games events and promise gender parity
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB